a composition for treating a subject is provided . the composition includes dimeric or polymeric iga therapeutic . formulating agents are mixed with the dimeric or polymeric iga to yield a dosing form of a capsule , tablet , and a suppository . a process for manufacturing a medicament for the treatment of c . difficile associated disease in a human is also provided that the sequential modification of monomeric iga with j chain and secretory component to form a dimeric or polymeric iga therapeutic . the dimeric or polymeric iga therapeutic is then mixed with formulating agents to create a capsule , tablet , or suppository dosing form . the therapeutic is amenable to enrobement directly through microeneapsulation or the dosing form is coated with an enteric coating . a method of c . difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration .